Show simple item record

dc.contributor.authorMartin-Liberal, Juanen
dc.contributor.authorAlam, Salmaen
dc.contributor.authorConstantinidou, Anastasiaen
dc.contributor.authorFisher, Cyrilen
dc.contributor.authorKhabra, Komelen
dc.contributor.authorMessiou, Christinaen
dc.contributor.authorOlmos, Daviden
dc.contributor.authorMitchell, Scotten
dc.contributor.authorAl-Muderis, Omaren
dc.contributor.authorMiah, Aishaen
dc.contributor.authorLinch, Marken
dc.contributor.authorJones, Robin Lewisen
dc.contributor.authorScurr, Michelle R.en
dc.contributor.authorJudson, Ian Roberten
dc.contributor.authorBenson, Charlotteen
dc.creatorMartin-Liberal, Juanen
dc.creatorAlam, Salmaen
dc.creatorConstantinidou, Anastasiaen
dc.creatorFisher, Cyrilen
dc.creatorKhabra, Komelen
dc.creatorMessiou, Christinaen
dc.creatorOlmos, Daviden
dc.creatorMitchell, Scotten
dc.creatorAl-Muderis, Omaren
dc.creatorMiah, Aishaen
dc.creatorLinch, Marken
dc.creatorJones, Robin Lewisen
dc.creatorScurr, Michelle R.en
dc.creatorJudson, Ian Roberten
dc.creatorBenson, Charlotteen
dc.date.accessioned2018-06-22T09:54:01Z
dc.date.available2018-06-22T09:54:01Z
dc.date.issued2013
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42149
dc.description.abstractBackground. Soft-tissue sarcomas (STS) are a heterogeneous group of diseases with lack of effective treatments in most cases. Previous data suggest that continuous infusional ifosfamide regimens might improve cytotoxicity and tolerability compared to standard schedules. Methods. We retrospectively report the outcome of 35 patients affected by STS treated with a 14-day infusional ifosfamide regimen (1000 mg/m2/day) in our institution. Predictive factors for toxicity were also explored. Results. Median age was 53 years. There were 16 males and 19 females. Classification by histology was dedifferentiated liposarcoma (DDLPS): 22 (62.8%), synovial sarcoma: 7 (20%), myxoid/round-cell liposarcoma: 3 (8.5%), and others: 3 (8.5%). Overall, 7 patients (20%) achieved partial response (PR) and 10 patients (29%) achieved stable disease (SD). DDLPS showed special sensitivity: 5 patients (22.7%) had PR, 7 patients (31.8%) had SD, and disease control rate was 54.5%. Median progression-free survival and overall survival were 4.2 and 11.2 months, respectively. The most common toxicities were fatigue, nausea, and vomiting (all grades: 85.7%, 83%, and 54.3%, resp.). Neither hypoalbuminaemia nor gender was found to predict toxicity, although encephalopathy predominantly affected females. Conclusion. Ifosfamide administered as a 14-day continuous infusion is a safe regimen in STS with notable activity in DDLPS. © 2013 Juan Martin-Liberal et al.en
dc.language.isoengen
dc.sourceSarcomaen
dc.titleClinical activity and tolerability of a 14-day infusional ifosfamide schedule in soft-tissue sarcomaen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1155/2013/868973
dc.description.volume2013
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidConstantinidou, Anastasia [0000-0001-5316-7574]
dc.contributor.orcidJudson, Ian Robert [0000-0002-4766-5304]
dc.contributor.orcidMessiou, Christina [0000-0002-0557-9379]
dc.contributor.orcidMitchell, Scott [0000-0002-2336-4072]
dc.contributor.orcidLinch, Mark [0000-0003-2305-8486]
dc.gnosis.orcid0000-0001-5316-7574
dc.gnosis.orcid0000-0002-4766-5304
dc.gnosis.orcid0000-0002-0557-9379
dc.gnosis.orcid0000-0002-2336-4072
dc.gnosis.orcid0000-0003-2305-8486


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record